Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major...
Transcript of Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major...
![Page 1: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/1.jpg)
Neisseria meningitidis
CDC
![Page 2: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/2.jpg)
Invasive Meningococcal Disease
AAP
2005
![Page 3: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/3.jpg)
Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory
secretions of a nasopharyngeal carrier Most common cause of bacterial meningitis in
individuals 2-18 years Approximately 3000 cases each year Mortality rates 10-13% 10% of survivors with severe morbidity
– mental retardation– hearing loss– loss of limbs
![Page 4: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/4.jpg)
Meningococcal Vaccines
Polysaccharide vaccine covering serogroups A, C, Y, and W-135
Single dose Revaccination if at high risk
for infection– children after 2-3 years if
<4 at time of 1st dose– consider for older children
and adults after 3-5 years
Meningococcal conjugate vaccine covering serogroups A, C, Y, and W-135
Repeat dose(s) for high risk Licensed for use in individuals
aged 9 months to 55 years (Menactra) and 2 months-55 years (Menveo)
Recommended for routine use in 11-12 year olds and repeat dose at age 16
![Page 5: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/5.jpg)
Meningococcal Vaccine Recommendations
Also recommended for– control of serogroup C outbreaks
– individuals with immune deficiencies
– individuals with asplenia
– travelers to endemic areas
– military recruits
![Page 6: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/6.jpg)
Incidence in College Students
![Page 7: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/7.jpg)
Immunization Action Coalition
![Page 8: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/8.jpg)
Vaccine Limitations
Not very effective in children less than 2 years
Does not confer 100% protection against serogroups contained in vaccine
Confers no protection from serogroup B
Short duration of protection
Confers no protection from serogroup B
Polysaccharide Conjugate
![Page 9: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/9.jpg)
Revaccination with MCV4
Revaccinate individuals at prolonged risk of invasive disease
– Complement deficiencies– Anatomic or functional splenectomy– Prolonged exposure (microbiologists, travelers or
residents of hyperendemic or epidemic areas)
![Page 10: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/10.jpg)
Revaccination Schedule
Revaccinate adolescents at 16 years of age
Revaccinate after 5 years if age >7 years
Revaccinate after 3 years of age 2-6 years
Continue to revaccinate at 5 year intervals if
remain in high risk group
![Page 11: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/11.jpg)
Meningococcal Immunization for Infants MCV4 Hib-Men CY-TT
– Combination vaccine for infants– Meningococcal serotypes C and Y– Haemophilus influenzae type b – All conjugated to tetanus toxoid
MCV4 or Hib-Men CY-TT recommended for infants at high risk of invasive meningococcal disease
– Four dose series in infant immunization schedule
![Page 12: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/12.jpg)
Vaccines for Meningococcal Serogroup B (MenB)
![Page 13: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/13.jpg)
Meningococcal Serogroup B
Trumenba: Recombinant serogroup B fHBP protein
– (H binding protein)
Induces complement dependent antibody responses
No clinical protection confirmed 3 dose series for 10-25 year olds
![Page 14: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/14.jpg)
Meningococcal Serogroup B
Bexsero: multicomponent; Recombinant Big increases in antibody concentrations Used in Princeton and UCSB outbreaks 2 dose series at least one month apart for
10-25 year olds
![Page 15: Neisseria meningitidis - University of Wisconsin–Madison · Meningococcal Disease Five major serogroups A, B, C, Y, and W-135 Transmission via direct contact with respiratory secretions](https://reader030.fdocuments.net/reader030/viewer/2022040603/5ea11f5e5ab79464707cf5ae/html5/thumbnails/15.jpg)
ACIP Recommendations
Either vaccine for individuals at high risk for invasive meningococcal disease starting at age 10 years
– Use same risks as for MCV4– No upper age limit
16-23 year olds may be vaccinated to provide short-term protection